CTLA4,CTLA-4: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CTLA-4,CTLA4. The page also collects GeneMedi's different modalities and formats products for CTLA-4 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CTLA-4 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008]
| Target ID | GM-T15000 |
| Target Name | CTLA-4 |
| Gene ID | 1493 |
| Gene Official Name | CTLA4 |
| Gene Alias | ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index, Immuno-oncology Target |
Pre-made CTLA-4-specific INN-index biosimilar (antibody&conjugates)-Cadonilimab, Lorigerlimab, Quavonlimab, Nurulimab, Botensilimab, Tuvonralimab, abatacept, Vudalimab, Ipilimumab, Erfonrilimab, Ticilimumab, Zalifrelimab, Pavunalimab, Tremelimumab
Anti-CTLA-4 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pre-made anti-CTLA-4 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CTLA-4 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CTLA-4 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Cat No. | Antibody Name | Format | Classified by tag | Order |
| GM-Tg-hg-T15000-Ab | Anti-CTLA-4/CTLA4 monoclonal antibody | mab | Biofunctional antibody, Therapeutics Target antibody |  |
Facebook
LinkedIn
Twitter
